LAVA THERAPEUTICS N.V. LAVA Therapeutics N.V. announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience working with global biotech and pharmaceutical companies and managing numerous drug approvals.
Most recently, he was the chief medical officer for Celyad Oncology, a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. Dr. Morris also served as chief medical officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications. He was also vice president of worldwide clinical research at Cephalon where he supported the approval of TREANDA(R) (bendamustine) for the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytopenia.
He began his career at AstraZeneca and held roles of increasing responsibility including global medical lead for Faslodex(R) (fulvestrant) which he managed through its approval for breast cancer.Dr. Morris holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics degree from Sheffield University Medical School in the UK and is a Member of the Royal College of Physicians of London.
